{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:11:34Z","timestamp":1786119094389,"version":"build-2736575974"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,2]]},"DOI":"10.1097\/inf.0b013e31818a0237","type":"journal-article","created":{"date-parts":[[2009,1,27]],"date-time":"2009-01-27T03:15:05Z","timestamp":1233026105000},"page":"86-91","source":"Crossref","is-referenced-by-count":66,"title":["A Randomized Trial to Determine the Tolerability and Immunogenicity of a Quadrivalent Meningococcal Glycoconjugate Vaccine in Healthy Adolescents"],"prefix":"10.1097","volume":"28","author":[{"given":"Lisa A.","family":"Jackson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith S.","family":"Reisinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Anemona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa E.","family":"Danzig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"Dull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210202","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus. I. The role of humoral antibodies.","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"R2-2-20210202","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S0140-6736(85)90224-7","article-title":"Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine.","volume":"2","author":"Reingold","year":"1985","journal-title":"Lancet"},{"key":"R3-2-20210202","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1001\/jama.285.2.177","article-title":"Effectiveness of a mass immunization campaign against serogroup C meningococcal disease in Quebec.","volume":"285","author":"De Wals","year":"2001","journal-title":"JAMA"},{"key":"R4-2-20210202","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1586\/14760584.1.3.399","article-title":"Evolution of conjugate vaccines.","volume":"1","author":"Makela","year":"2002","journal-title":"Expert Rev Vaccines"},{"key":"R5-2-20210202","first-page":"794","article-title":"Revised recommendations of the Advisory Committee on Immunization Practices to vaccinate all persons aged 11\u201318 years with meningococcal conjugate vaccine.","volume":"56","year":"2007","journal-title":"MMWR"},{"key":"R6-2-20210202","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jama.2007.29-c","article-title":"Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial.","volume":"299","author":"Snape","year":"2008","journal-title":"JAMA"},{"key":"R9-2-20210202","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1001\/jama.293.24.3003","article-title":"Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults.","volume":"293","author":"Pichichero","year":"2005","journal-title":"JAMA"},{"key":"R10-2-20210202","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2165\/00148581-200608030-00005","article-title":"Reduced-antigen, combined diphtheria-tetanus-acellular pertussis vaccine, adsorbed (Boostrix) (US formulation): use as a single-dose booster immunization in adolescents aged 10\u201318 years.","volume":"8","author":"Frampton","year":"2006","journal-title":"Paediatr Drugs"},{"key":"R11-2-20210202","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.1016\/j.vaccine.2006.04.068","article-title":"Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18.","volume":"24","author":"Villa","year":"2006","journal-title":"Vaccine"},{"key":"R12-2-20210202","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1001\/archpedi.159.10.907","article-title":"Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents.","volume":"159","author":"Keyserling","year":"2005","journal-title":"Arch Pediatr Adolesc Med"},{"key":"R13-2-20210202","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1128\/CDLI.8.3.616-623.2001","article-title":"Importance of complement source in measuring meningococcal bactericidal titers.","volume":"8","author":"Santos","year":"2001","journal-title":"Clin Diagn Lab Immunol"},{"key":"R15-2-20210202","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1086\/317646","article-title":"Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers.","volume":"183","author":"Richmond","year":"2001","journal-title":"J Infect Dis"},{"key":"R16-2-20210202","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1086\/527401","article-title":"Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity.","volume":"197","author":"Maiden","year":"2008","journal-title":"J Infect Dis"},{"key":"R17-2-20210202","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(02)08679-8","article-title":"Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination.","volume":"359","author":"Maiden","year":"2002","journal-title":"Lancet"},{"key":"R19-2-20210202","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1099\/0022-1317-51-9-717","article-title":"Impact of meningococcal C conjugate vaccine in the UK.","volume":"51","author":"Balmer","year":"2002","journal-title":"J Med Microbiol"},{"key":"R20-2-20210202","doi-asserted-by":"crossref","first-page":"S280","DOI":"10.1097\/01.inf.0000147643.95195.37","article-title":"Meningococcal C vaccines: the Canadian experience.","volume":"23","author":"De Wals","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"R21-2-20210202","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1016\/j.vaccine.2005.03.045","article-title":"Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain.","volume":"23","author":"Larrauri","year":"2005","journal-title":"Vaccine"},{"key":"R22-2-20210202","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1574-6976.2006.00053.x","article-title":"Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines.","volume":"31","author":"Trotter","year":"2007","journal-title":"FEMS Microbiol Rev"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/INF.0b013e31818a0237","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:32:19Z","timestamp":1786037539000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00006454-200902000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0b013e31818a0237","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2009,2]]}}}